Replies to post #254174 on Biotech Values

[RNsidersbuying]

SLRN 2.15 - Thanks for the insight, Dew. I added a bunch more here to lower my avg. down to 2.45...it's why I like these cashfat-bio-stocks so much, when they nosedive, one can feel comfortable adding.

[WorstLuck]

SLRN

The risk is relatively low due to the strong balance sheet, as is the case for ENTA. The word, “extremely” in this context is not well-defined, so I don’t know about that.

I'm not following the company. However, my sense from respected people who do is that SLRN will be spending a good chunk of that cash on further development in TED and that there is no reason for them to do so.

[DewDiligence]

ALMS acquires SLRN for $2.35/sh* in stock—a 24% premium to today’s 4:00pm closing price:

https://www.globenewswire.com/news-release/2025/02/06/3022460/0/en/Alumis-and-ACELYRIN-to-Merge-Creating-a-Late-Stage-Clinical-Biopharma-Company-Dedicated-to-Innovating-Developing-and-Commercializing-Transformative-Therapies-for-Immune-mediated-Di.html

*Based on SLRN’s AH price of $5.51 (as I’m typing). The exchange ratio is 0.4274 shares of ALMS for each share of SLRN.